Eric Rowinsky - Biogen Independent Director
| BIIB Stock | USD 216.13 1.31 0.61% |
Director
Dr. Eric K. Rowinsky, M.D. is an Independent Director of Biogen Inc. Dr. Rowinsky has served as President of RGenix, Inc., a privatelyheld life sciences company, since November 2015 and as its Executive Chairman since December 2016. Since June 2016 Dr. Rowinsky has also been the Chief Scientific Officer of Clearpath Development Co., which rapidly advances development stage therapeutic assets to predefined human proofofconcept milestones. From January 2012 to November 2015 Dr. Rowinsky was the Head of Research and Development and Chief Medical Officer of Stemline Therapeutics, Inc., a biotechnology company focusing on the discovery and development of therapeutics targeting cancer stem cells. Dr. Rowinsky is an Adjunct Professor of Medicine at New York University and was an independent consultant since January 2010. Prior to that, he was the Chief Executive Officer of Primrose Therapeutics, Inc., a startup biotechnology company focusing on the development of therapeutics for polycystic kidney disease, from August 2010 until its acquisition in September 2011. From 2005 to December 2009 he served as the Chief Medical Officer and Executive Vice President of ImClone Systems Incorporated, a life sciences company. From 1996 to 2004 Dr. Rowinsky held several positions at the Cancer Therapy Research Centers Institute for Drug Development, including Director of the Institute and Director of Clinical Research. During that time, he held the SBC Endowed Chair for Early Drug Development and Clinical Professor of Medicine at the University of Texas Health Science Center at San Antonio. From 1988 to 1996 Dr. Rowinsky was an Associate Professor of Oncology at the Johns Hopkins School of Medicine and on the staff of the Johns Hopkins Hospital. Dr. Rowinsky also serves as a director of Biophytis, a biotechnology company, and Fortress Biotech Inc. and Verastem, Inc., both biopharmaceutical companies. since 2010.
| Age | 61 |
| Tenure | 14 years |
| Address | 225 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.0486 % which means that it generated a profit of $0.0486 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0805 %, meaning that it created $0.0805 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biogen's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.06, whereas Return On Tangible Assets are forecasted to decline to 0.08. At present, Biogen's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 21 B, whereas Non Currrent Assets Other are forecasted to decline to about 270.1 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Baltimore | Amgen Inc | 78 | |
| Darius Adamczyk | Johnson Johnson | 55 | |
| Laurent Attal | Sanofi ADR | 60 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Robert Williams | Amgen Inc | 69 | |
| Vicki Sato | Bristol Myers Squibb | 71 | |
| Harish Manwani | Gilead Sciences | 64 | |
| Susan Hockfield | Pfizer Inc | 70 | |
| Susan Lindquist | Johnson Johnson | 65 | |
| William Burnside | AbbVie Inc | 69 | |
| Judith Pelham | Amgen Inc | 69 | |
| John Madigan | Gilead Sciences | 77 | |
| Gayle Wilson | Gilead Sciences | 75 | |
| Frank Herringer | Amgen Inc | 74 | |
| Frederick Waddell | AbbVie Inc | 67 | |
| Thomas Cech | Merck Company | 72 | |
| Per WoldOlsen | Gilead Sciences | 70 | |
| Suet Lee | Sanofi ADR | 60 | |
| Carlos Represas | Merck Company | 72 | |
| Don Cornwell | Pfizer Inc | 69 | |
| Kelly Kramer | Gilead Sciences | 50 | |
Management Performance
| Return On Equity | 0.0805 | ||||
| Return On Asset | 0.0486 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO President | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Paul McKenzie, Executive Vice President - Pharmaceutical Operations & Technology | ||
| Alfred Sandrock, Group Senior Vice President Chief Medical Officer | ||
| Spyros ArtavanisTsakonas, Senior Vice President Chief Scientific Officer | ||
| Alexander Denner, Independent Director | ||
| Natacha Gassenbach, Chief Affairs | ||
| Douglas Williams, Executive VP of RandD | ||
| JeanPaul Kress, Executive Vice President and Presidentident - International and Head of Global Therapeutic Operations | ||
| Eric Rowinsky, Independent Director | ||
| William Hawkins, Director | ||
| Charles Triano, Senior Relations | ||
| Kenneth Pietro, Executive Vice President - Human Resources | ||
| John Chiminski, Director | ||
| Adam Koppel, Senior Vice President and Chief Strategy Officer | ||
| Caroline Dorsa, Independent Director | ||
| Michael Ehlers, Executive Vice President of Research and Development | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Daniel Karp, Executive Vice President - Corporate Development | ||
| Anirvan Ghosh, Senior Vice President - Research and Early Development | ||
| Michael CPA, Executive CFO | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Stelios Papadopoulos, Independent Chairman of the Board | ||
| Adam Keeney, Executive Development | ||
| Robert Pangia, Independent Director | ||
| Matt Griffiths, Senior Vice President CIO | ||
| Jeffrey Capello, CFO, Executive Vice President | ||
| Jesus Mantas, Director | ||
| Richard Mulligan, Independent Director | ||
| Michel Vounatsos, Vice President and Chief Commercial Officer | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Susan Esq, Executive Officer | ||
| George Scangos, CEO and Director | ||
| Adriana Karaboutis, Executive VP of Technology, Bus. Solutions and Corporate Affairs | ||
| Mark Hernon, Senior Vice President CIO | ||
| Stephen Sherwin, Independent Director | ||
| Chirfi Guindo, Executive Vice President Head of Global Marketing, Market Access and Customer Innovation | ||
| Susan Alexander, Executive Vice President Chief Legal Officer and Corporate Secretary | ||
| Catherine Steele, Senior Vice President - Corporate Affairs | ||
| Paul Clancy, CFO and Executive VP of Fin. | ||
| Steven Holtzman, Executive Vice President - Corporate Development | ||
| Nancy Leaming, Independent Director | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations | ||
| Lynn Schenk, Independent Director | ||
| Camille Lee, Senior Vice President - Alzheimer's Therapeutic Area | ||
| Brian Posner, Independent Director | ||
| Gregory Covino, Chief Accounting Officer, VP of Fin. and Controller | ||
| Alisha Alaimo, President America | ||
| John Cox, Executive VP of Pharmaceutical Operations and Technology |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0805 | ||||
| Return On Asset | 0.0486 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 37.15 B | ||||
| Shares Outstanding | 145.6 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 92.68 % | ||||
| Number Of Shares Shorted | 3.26 M | ||||
| Price To Earning | 14.83 X |
Biogen Investors Sentiment
The influence of Biogen's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Biogen. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Biogen's public news can be used to forecast risks associated with an investment in Biogen. The trend in average sentiment can be used to explain how an investor holding Biogen can time the market purely based on public headlines and social activities around Biogen Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biogen's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biogen's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Biogen's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Biogen.
Biogen Implied Volatility | 51.87 |
Biogen's implied volatility exposes the market's sentiment of Biogen Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Biogen's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Biogen stock will not fluctuate a lot when Biogen's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biogen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biogen's short interest history, or implied volatility extrapolated from Biogen options trading.
Pair Trading with Biogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.Moving together with Biogen Stock
| 0.74 | EVOK | Evoke Pharma | PairCorr |
| 0.7 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
Moving against Biogen Stock
| 0.67 | HCWB | HCW Biologics | PairCorr |
| 0.66 | KRYS | Krystal Biotech Financial Report 13th of May 2024 | PairCorr |
| 0.65 | VKTX | Viking Therapeutics | PairCorr |
| 0.63 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.62 | OGN | Organon | PairCorr |
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.011 | Earnings Share 8 | Revenue Per Share 66.688 | Quarterly Revenue Growth (0.07) | Return On Assets 0.0486 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.